August 27, 2024 11:44 AM EDT
Financing
Startups
China

Du­al­i­ty Bi­o­log­ics, an ADC part­ner of BeiGene and BioN­Tech, files for Hong Kong IPO

Kyle LaHucik

Senior Reporter

Clin­i­cal-stage an­ti­body-drug con­ju­gate start­up Du­al­i­ty Bi­o­log­ics has filed for an ini­tial pub­lic of­fer­ing in Hong Kong, where there have been on­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

All of 23and­Me's in­de­pen­dent board mem­bers re­sign over dis­agree­ments with CEO

Bad trip: How cul­ture con­flict and a need for cash near­ly broke Lykos

No­var­tis’ Kisqali snags FDA ap­proval to re­duce re­cur­rence in pa­tients with ear­ly forms of breast can­cer

Af­ter land­ing a key win in a com­mon can­cer con­di­tion, Pfiz­er faces a big test in Phase 3

23andMe heads to ES­MO to tout its two clin­i­cal-stage drugs af­ter scrap­ping dis­cov­ery team

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times